Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Drugs - Generic
Sub-IndustryN/A
SectorMedical
Current SymbolLON:SUMM
Previous Symbol
CUSIPN/A
Phone+44-1235-443939
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees76
Outstanding SharesN/A
Market Cap£0.00
OptionableNot Optionable
Summit Therapeutics (LON:SUMM) Frequently Asked Questions
What is Summit Therapeutics' stock symbol?
Summit Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SUMM."
How were Summit Therapeutics' earnings last quarter?
Summit Therapeutics PLC (LON:SUMM) posted its earnings results on Tuesday, June, 5th. The company reported ($8.00) EPS for the quarter, topping the consensus estimate of ($10.60) by $2.60. View Summit Therapeutics' Earnings History.
Has Summit Therapeutics been receiving favorable news coverage?
News stories about SUMM stock have trended somewhat positive on Friday, InfoTrie reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Summit Therapeutics earned a coverage optimism score of 1.6 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an effect on the company's share price in the immediate future.
Who are some of Summit Therapeutics' key competitors?
Some companies that are related to Summit Therapeutics include 22nd Century Group (XXII), 3D Signatures (DXD), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abaxis (ABAX), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acerus Pharmaceuticals (ASP), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Activecare (ACAR) and Advanced Accelerator Application (AAAP).
Who are Summit Therapeutics' key executives?
Summit Therapeutics' management team includes the folowing people:
- Mr. Glyn O. Edwards, CEO & Exec. Director (Age 62)
- Mr. Erik Ostrowski, Chief Financial Officer (Age 45)
- Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 52)
- Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 68)
- Ms. Michelle Avery, Director of Investor Relations
How do I buy shares of Summit Therapeutics?
Shares of SUMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Summit Therapeutics' stock price today?
One share of SUMM stock can currently be purchased for approximately GBX 23.
What is Summit Therapeutics' official website?
How can I contact Summit Therapeutics?
Summit Therapeutics' mailing address is 136A Eastern Avenue, ABINGDON, OX14 4SB, United Kingdom. The company can be reached via phone at +44-1235-443939.
MarketBeat Community Rating for Summit Therapeutics (LON SUMM)
MarketBeat's community ratings are surveys of what our community members think about Summit Therapeutics and other stocks. Vote "Outperform" if you believe SUMM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SUMM will underperform the S&P 500 over the long term. You may vote once every thirty days.
